Skip to content
Dynex Solutions

Patients Coming Off Slimming Injections Gain Back Weight Far More Rapidly Compared to Dieters

Illustration of pharmaceutical syringe and scale
Obesity treatment often requires long-term strategies.

New research reveals that patients who discontinue blockbuster weight-loss injections like Mounjaro or Wegovy tend to recover lost weight at a significantly accelerated pace than those who halt conventional lifestyle regimens.

Published data in a prominent health publication shows that while overweight people often shed about a fifth of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.

"People purchasing such treatments need to be aware of the risk of rapid weight regain when the therapy ends," cautioned expert Dr. Susan Jebb.

This pace of regain means a reversion to pre-treatment mass within about 18 months.

Weighing Treatments

The analysis, which reviewed dozens of trials involving thousands of participants, compared the results of GLP-1 agonists with conventional dieting.

Scientists point out that people who lose weight through dieting usually see a less rapid creep back—perhaps 100 grams monthly—after stopping.

Understanding the Rapid Rebound

Experts propose the mode of action of the drugs explains the accelerated regain.

These medications mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.

"Long-term administration of GLP-1 concentrations far above than normal might result in the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.

"Stopping of this medication leads to appetite is no longer kept in check, making binge eating a significant risk."

An Ongoing Condition?

The NHS advise the injections for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.

Professionals say that, given the likelihood of relapse, the therapy should be considered life-long.

This view is echoed by drug manufacturers, who say that the findings "highlight the chronic character of obesity," comparing it to managing conditions like hypertension.

User Testimonies

People who have stopped the jabs explain a intense return of appetite.

"I experienced something activating and you're instantly extremely hungry," described a patient.

This difficulty is compounded if users have not developed lasting lifestyle or habit modifications during treatment.

Significant Use

Recent estimates suggest that millions of people in the UK have tried these injections in the past year, with interest continuing to grow.

  • Adoption is greater among females compared to men.
  • The 40s and 50s age group shows the highest level of interest.
  • A large proportion obtain the medications through private prescriptions rather than the NHS.

In conclusion, researchers stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a magic fix and lasting health benefits hinges on integrated behavioural changes.

AF
By

Anthony Ford

A tech enthusiast and cybersecurity expert with over a decade of experience in IT infrastructure and digital transformation strategies.

Dynex Solutions

Type to search articles.